

WEST[Help](#)[Logout](#)[Interrupt](#)[Main Menu](#)[Search Form](#)[Posting Counts](#)[Show S Numbers](#)[Edit S Numbers](#)[Preferences](#)**Search Results -**

Terms	Documents
l9 and (obesity or leptin)	0

BEST AVAILABLE COPY

US Patents Full-Text Database
 US Pre-Grant Publication Full-Text Database
 JPO Abstracts Database
 EPO Abstracts Database
 Derwent World Patents Index
 Base: IBM Technical Disclosure Bulletins

Refine Search:

Clear

Search History**Today's Date: 5/7/2001**

<u>DB Name</u>	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u>
USPT,PGPB,JPAB,EPAB,DWPI	l9 and (obesity or leptin)	0	<u>L10</u>
USPT,PGPB,JPAB,EPAB,DWPI	prockop-d\$.in.	57	<u>L9</u>
USPT,PGPB,JPAB,EPAB,DWPI	l7 and ((obesity adj1 protein) or leptin)	7	<u>L8</u>
USPT,PGPB,JPAB,EPAB,DWPI	l4 or l6	723	<u>L7</u>
USPT,PGPB,JPAB,EPAB,DWPI	marrow adj1 stroma\$1	561	<u>L6</u>
USPT,PGPB,JPAB,EPAB,DWPI	l4 near5 carrier\$1	11	<u>L5</u>
USPT,PGPB,JPAB,EPAB,DWPI	(mesenchymal adj1 stem adj1 cell\$1)	208	<u>L4</u>
USPT,PGPB,JPAB,EPAB,DWPI	l2 and (transfect\$ or transduc\$)	26	<u>L3</u>
USPT,PGPB,JPAB,EPAB,DWPI	l1 and gene	30	<u>L2</u>
USPT,PGPB,JPAB,EPAB,DWPI	human near5 (obesity adj1 protein)	38	<u>L1</u>

WEST

Generate Collection

L16: Entry 4 of 6

File: USPT

Sep 5, 2000

DOCUMENT-IDENTIFIER: US 6114113 A

TITLE: High efficiency genetic modification method

DEPR:

Erythropoietin (EPO) and leptin can also be expressed in vivo from genetically modified T cells according to the methods of the invention. For instance EPO is useful in gene therapy treatment of a variety of disorders including anemia (see International Publication No. WO 95/13376 entitled "Gene Therapy for Treatment of Anemia"). Sustained delivery of leptin by the methods of the invention is useful in treatment of obesity. See International Publication No. WO 96/05309 for a description of the leptin gene and the use thereof in the treatment of obesity.

DEPR:

Pluripotent stem cells then differentiate into lymphoid stem cells, bone marrow stromal cells, T cell progenitors, B cell progenitors, thymocytes, T.sub.H Cells, T.sub.C cells, and B cells. This differentiation is modulated by growth factors such as IL-3, IL-4, IL-6, IL-7, GM-CSF, M-CSF, G-CSF, IL-2, and IL-5.

CCXR:

435/440

CCXR:

435/455

WEST**Freeform Search****Database:**

US Patents Full-Text Database
US Pre-Grant Publication Full-Text Database
JPO Abstracts Database
EPO Abstracts Database
Derwent World Patents Index
IBM Technical Disclosure Bulletins

Term:**Display:** **Documents in Display Format:** **Starting with Number** **Generate:** ☐ Hit List ☒ Hit Count ☐ Image

Search

Clear

Help

Logout

Interrupt

Main Menu

Show S Numbers

Edit S Numbers

Preferences

Search History**Today's Date:** 5/7/2001

<u>DB Name</u>	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u>
USPT,PGPB,JPAB,EPAB,DWPI	115 and (obesity or leptin)	6	<u>L16</u>
USPT,PGPB,JPAB,EPAB,DWPI	114 and 17	129	<u>L15</u>
USPT,PGPB,JPAB,EPAB,DWPI	111 or 112 or 113	6816	<u>L14</u>
USPT,PGPB,JPAB,EPAB,DWPI	((424/93.21)!.CCLS.)	398	<u>L13</u>
USPT,PGPB,JPAB,EPAB,DWPI	((536/23.5 536/24.1 536/24.2)!.CCLS.)	5526	<u>L12</u>
USPT,PGPB,JPAB,EPAB,DWPI	((435/440 435/455 435/372 435/352)!.CCLS.)	1374	<u>L11</u>
USPT,PGPB,JPAB,EPAB,DWPI	19 and (obesity or leptin)	0	<u>L10</u>
USPT,PGPB,JPAB,EPAB,DWPI	prockop-d\$.in.	57	<u>L9</u>
USPT,PGPB,JPAB,EPAB,DWPI	17 and ((obesity adj1 protein) or leptin)	7	<u>L8</u>
USPT,PGPB,JPAB,EPAB,DWPI	14 or 16	723	<u>L7</u>
USPT,PGPB,JPAB,EPAB,DWPI	marrow adj1 stroma\$1	561	<u>L6</u>
USPT,PGPB,JPAB,EPAB,DWPI	14 near5 carrier\$1	11	<u>L5</u>
USPT,PGPB,JPAB,EPAB,DWPI	(mesenchymal adj1 stem adj1 cell\$1)	208	<u>L4</u>
USPT,PGPB,JPAB,EPAB,DWPI	12 and (transfect\$ or transduc\$)	26	<u>L3</u>
USPT,PGPB,JPAB,EPAB,DWPI	11 and gene	30	<u>L2</u>
USPT,PGPB,JPAB,EPAB,DWPI	human near5 (obesity adj1 protein)	38	<u>L1</u>